Daniel M Moreira1, Boris Gershman2, Christine M Lohse3, Stephen A Boorjian2, John C Cheville4, Bradley C Leibovich2, Robert Houston Thompson2. 1. Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. moreira.daniel@mayo.edu. 2. Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Division of Biomedical Statistics and Informatics, Mayo Foundation for Medical Education and Research, Mayo Clinic, Rochester, MN, USA. 4. Department of Pathology, Mayo Clinic, Rochester, MN, USA.
Abstract
OBJECTIVES: To analyze the association of paraneoplastic syndromes (PNS) with progression-free (PFS) and cancer-specific survival (CSS) among patients with renal cell carcinoma (RCC) undergoing nephrectomy. METHODS: We performed a retrospective analysis of 2865 patients undergoing nephrectomy for localized RCC at Mayo Clinic from 1990 to 2010. PNS analyzed were anemia, polycythemia, hypercalcemia, recent-onset hypertension, and liver dysfunction. PFS and CSS were estimated using Kaplan-Meier method and compared with Cox proportional hazard models, unadjusted and adjusted for clinicopathologic features. RESULTS: A total of 661 (23 %) patients had anemia, 37 (1 %) had polycythemia, 177 (9 %) had hypercalcemia, 51 (2 %) had recent-onset hypertension, and 224 (10 %) had liver dysfunction at time of nephrectomy. Patients with PNS were more likely to have high-grade tumors and advanced disease stages. A total of 675 (24 %) patients developed progression and 1171 (41 %) died of RCC, over a median follow-up of 8.2 years. On univariable analysis, the presence of any PNS was associated with inferior CSS [hazard ratio (HR) = 1.86, p = 0.007] and a trend toward shorter PFS (HR = 1.33, p = 0.07) compared with patients without PNS. Specifically, anemia, polycythemia, hypercalcemia, and liver dysfunction were each associated with inferior CSS and PFS (all p < 0.05). However, on multivariable analysis PNS (overall or each individual syndrome) did not remain independently associated with CSS or PFS. CONCLUSIONS: Patients with RCC undergoing nephrectomy presenting with PNS have worse oncologic outcome than those with incidentally found tumors. However, the adverse outcome among PNS patients seems to be largely explained by adverse pathologic features of these tumors.
OBJECTIVES: To analyze the association of paraneoplastic syndromes (PNS) with progression-free (PFS) and cancer-specific survival (CSS) among patients with renal cell carcinoma (RCC) undergoing nephrectomy. METHODS: We performed a retrospective analysis of 2865 patients undergoing nephrectomy for localized RCC at Mayo Clinic from 1990 to 2010. PNS analyzed were anemia, polycythemia, hypercalcemia, recent-onset hypertension, and liver dysfunction. PFS and CSS were estimated using Kaplan-Meier method and compared with Cox proportional hazard models, unadjusted and adjusted for clinicopathologic features. RESULTS: A total of 661 (23 %) patients had anemia, 37 (1 %) had polycythemia, 177 (9 %) had hypercalcemia, 51 (2 %) had recent-onset hypertension, and 224 (10 %) had liver dysfunction at time of nephrectomy. Patients with PNS were more likely to have high-grade tumors and advanced disease stages. A total of 675 (24 %) patients developed progression and 1171 (41 %) died of RCC, over a median follow-up of 8.2 years. On univariable analysis, the presence of any PNS was associated with inferior CSS [hazard ratio (HR) = 1.86, p = 0.007] and a trend toward shorter PFS (HR = 1.33, p = 0.07) compared with patients without PNS. Specifically, anemia, polycythemia, hypercalcemia, and liver dysfunction were each associated with inferior CSS and PFS (all p < 0.05). However, on multivariable analysis PNS (overall or each individual syndrome) did not remain independently associated with CSS or PFS. CONCLUSIONS:Patients with RCC undergoing nephrectomy presenting with PNS have worse oncologic outcome than those with incidentally found tumors. However, the adverse outcome among PNSpatients seems to be largely explained by adverse pathologic features of these tumors.
Authors: Emilio Sacco; Francesco Pinto; Francesco Sasso; Marco Racioppi; Gaetano Gulino; Andrea Volpe; Pierfrancesco Bassi Journal: Urol Int Date: 2009-07-27 Impact factor: 2.089
Authors: Kara Pepper; Uraporn Jaowattana; Michael D Starsiak; Raghuueer Halkar; Kelly Hornaman; Wenli Wang; Priya Dayamani; Vin Tangpricha Journal: J Gen Intern Med Date: 2007-04-19 Impact factor: 5.128
Authors: Hyung L Kim; Arie S Belldegrun; Danielo G Freitas; Matthew H T Bui; Ken-ryu Han; Frederick J Dorey; Robert A Figlin Journal: J Urol Date: 2003-11 Impact factor: 7.450
Authors: Ryan Sun; Rodney H Breau; Ranjeeta Mallick; Simon Tanguay; Frederic Pouliot; Anil Kapoor; Luke T Lavallée; Antonio Finelli; Alan I So; Ricardo A Rendon; Adrian S Fairey; Jean-Baptiste Lattouf; Jun Kawakami; Bimal Bhindi; Naveen S Basappa; Lori A Wood; Georg A Bjarnason; Daniel Y C Heng; Rahul K Bansal Journal: Can Urol Assoc J Date: 2021-04 Impact factor: 1.862
Authors: Silvia Vidali; Sepideh Aminzadeh-Gohari; René Günther Feichtinger; Renaud Vatrinet; Andreas Koller; Felix Locker; Tricia Rutherford; Maura O'Donnell; Andrea Stöger-Kleiber; Bridget Lambert; Thomas Klaus Felder; Wolfgang Sperl; Barbara Kofler Journal: Oncotarget Date: 2017-07-17
Authors: Laura Burgess; Marissa Keenan; Alan Liang Zhou; Kiefer Lypka; Delvina Hasimja Saraqini; Jeff Yao; Samuel Martin; Christopher Morash; James Watterson; Christina Canil; Robert MacRae Journal: Curr Oncol Date: 2021-05-07 Impact factor: 3.677